Inhibikase Therapeutics (IKT) has an average rating of buy and mean price target of $5.88, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Nuvalent (NUVL) has an average rating of overweight and mean price target of $138.81, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $123.08, Change: $+34.59, Percent Change: +39.08%
Nuvalent (NUVL) has an average rating of overweight and mean price target of $138.81, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $122.87, Change: $+34.38, Percent Change: +38.85%
Nuvalent (NUVL) has an average rating of overweight and mean price target of $141.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)